Afmedica, Inc.

About

Afmedica, Inc. is a drug delivery company formed in early 2002 to commercialize new technologies that are the derivatives of the anti-proliferative drug eluting stent successfully commercialized by Johnson and Johnson in conjunction with the Company’s founders. Afmedica’s intellectual property platform supports a variety of novel medical uses of the FDA approved anti-proliferative agent Sirolimus. Afmedica’s first product is a polymer wrap that focuses on preserving the vascular graft in patients with End Stage Renal Disease (ESRD) who require a vascular access for chronic hemodialysis.